Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-07-19
2011-07-19
Jiang, Dong (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S387900, C530S388100
Reexamination Certificate
active
07981413
ABSTRACT:
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.
REFERENCES:
patent: 6306393 (2001-10-01), Goldenberg
patent: 7029677 (2006-04-01), Dedera et al.
patent: 7264967 (2007-09-01), Furusako et al.
patent: 7378253 (2008-05-01), Dedera et al.
patent: 2003/0073189 (2003-04-01), Baker et al.
patent: 2003/0099661 (2003-05-01), Valdez et al.
patent: 2003/0119130 (2003-06-01), Baker et al.
patent: 1 223 218 (2002-07-01), None
patent: WO 01/55336 (2001-08-01), None
patent: WO 01/79454 (2001-10-01), None
patent: WO 01/90304 (2001-11-01), None
“Approved Biotechnology Drugs,”Biotechnology Industry Drugs, printed Jan. 19, 2005.
Amlot et al., “A phase 1 study of anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy,”Blood, 82:2624-2633, 1993.
Bauer et al., “VpreB gene expression in hematopoietic malignancies: a lineage- and stage-restricted marker for B-cell precursor leukemias,”Blood, 78(6):1581-1588, 1991.
Behr et al., “Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose rate on toxicity and anti-tumor efficacy,”Int. J. Cancer, 77:787-795, 1998.
Burk and Matuszewski, “Muromonab-CD3 and antihymocyte globulin in renal transplantation,”Ann. Pharacother., 31:1370-1377, 1997.
Database GenEmbl; Accession No. HSA27741; Bottino et al., “Homo sapiensmRNA for activating NK receptor (KALI agent)”; Aug. 23, 2001.
Database GenEmbl; Accession No. HSA306388; Bottino et al., “Homo sapiensmRNA for NTB-A receptor (KALI b gene)”; Aug. 23, 2001.
Database Geneseq; accession No. ADH 52399, 2004.
Database SPTREmbl; Accession No. Q96DVO; Bottino et al., “Activating NK receptor precursor”; Dec. 1, 2001.
Davis et al., “Rituximab anti-CD20 monoclonal antibody therapy in Non-Hodgkin's Lymphoma: safety and efficacy of re-treatment,”J. Clin. Oncol., 18:3135-3143, 2000.
Dillman, “Antibodies as cytotoxic therapy,”Journal of Clinical Oncology, 12(7):1497-1515, 1994.
Fundamental Immunology, 4thedition, William Paul, ed., pp. 58-59, 91-94 and 106-108, 1998.
GenBank Accession No. AW851581.1, available May 19, 2000 from GenBank.
Guckel et al., “Anti-CD2 antibodies induce T cell unresponsiveness in vivo,”J. Exp. Med., 174:957-967, 1991.
Harris et al., “Therapeutic antibodies—the coming of age,”TIBTECH,11:42-44, 1993.
Hornick et al., “Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating facor or Interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties,”Blood, 89:4437-4447, 1997.
Jiang and Moller, “In vitro effects of HgCl2on murine lymphocutes. I. Preferable activation of CD4+ T cells in a responder strain,”J. Immunol., 154:3138-3146, 1995.
Maloney et al., “IDEC-C2B8 (Rituximab) anti-cd20 monoclonal antibody therapy in patients with relapsed low-grade Non-Hodgkin's Lymphoma”Blood, 90(6):2188-2195, 1997.
Maloney et al., “The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines,”Blood, 88:637a, 1996.
Ozaki et al., “Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24,”Blood, 90:3179-3186, 1997.
Press et al., Monoclonal antibody 15 (anti-CD20) serotherapy of human B cell lymphomas,Blood, 69:584-591, 1987.
Qin et al., “Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival,”J. Exp. Med., 179:341-346, 1994.
Racila et al., “Detection and characterization of carcinoma cells in the blood,”Proc. Natl. Acad. Sci. USA, 95:4589-4594, 1998.
Schiff et al., “Lambda-like and V Pre-B genes expression: An early B-Lineage marker of human leukemias,”Blood, 78(6):1516-1525, 1991.
Simpson et al., “Retinal VEGF mRNA measured by XYBR green I fluorescence: A versatile approach to quantitative PCR,”Molec. Vision, 6:178-183, 2000.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,”Trends in Biotech., 18(1):34-39, 2000.
Waldmann, “Monoclonal antibodies in diagnosis and therapy,”Science, 252:1657-1662, 1991.
White et al., “Antibody-targeted immunotherapy for treatment of malignancy,”Ann. Rev. Med., 52:125-145, 2001.
Wilde and Goa, “Muromonab CD3: A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection,”Drugs, 51:865-894, 1996.
Yang et al., “Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferators, perfluorooctanoic acid,”Int. Immunopharm., 2:389-397, 2002.
GenEmbl Database Accession No. AF043445 (1999).
Watson et al., “The Science Used in Recombinant DNA Industry”, Ch. 18, pp. 231-241 (1983).
International Search Report for PCT/US01/02613, Issued Oct. 4, 2001.
Anderson et al., “Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation,” Blood 63:1424-1433 (1984).
Bottino et al, “NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease,” J. Exp. Med. 194:235-246 (2001).
Drmanac and Drmanac, “cDNA screening by array hybridization,” Meth. Enzymol. 303:165-178 (1999).
Drmanac et al., “Gene-representing cDNA clusters defined by hybridization of 57,419 clones from infant brian libraries with short oligonucleotide probes,” Genomics 37:29-40 (1996).
Drmanac et al., “Sequencing and fingerprinting DNA by hybridization with oligonucleotide probes,” In: Encyclopedia of Analytical Chemistry, Ed. R.A. Meyers, John Wiley & Sons, Ltd., Chichester, pp. 5232-5237 (2000).
De La Fuente, et al., “CD84 leukocyte antigen is a new member of the Ig superfamly,” Blood 90:2398-2405 (1997).
Engle and De La Fuente, “CD84,” J. Biol. Regul. Homeost. Agents 14:290-291 (2000).
Green et al., “Monoclonal antibody therapy for solid tumors,” Cancer Treat. Rev. 26:269-286 (2000).
Maloney et al., “IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma,” Blood 90:2188-2195 (1997).
Martin et al., “CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: Adhesion is mediated by Ig-like domain,” J. Immunol. 167:3668-3676 (2001).
Press et al., “Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissues,” Oncogene 5:953-962 (1990).
Press et al., “Her-2
eu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease,” Cancer Res. 53:4960-4970 (1993).
Slamon et al., “Studies of the HER-2
eu proto-oncogene in human breast and ovarian cancer,” Science 244:707-712 (1989).
Sonnhammer et al., “Pfam: multiple sequence alignments and HMM-profiles of protein domains,” Nucl. Acids Res. 26:320-322 (1998
Boyle Bryan J.
Drmanac Radoje T.
Kuo Chiaoyun
Liu Chenghua
Tang Y. Tom
ARCA Biopharma Inc.
Fulbright & Jaworski L.L.P.
Jiang Dong
LandOfFree
Methods and compositions concerning antibodies that bind... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions concerning antibodies that bind..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions concerning antibodies that bind... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692053